BeyondSpring Provides Second-Quarter 2020 Financial Results and Business Updates
September 03, 2020 07:00 ET
|
BeyondSpring, Inc.
- Reported Positive Topline Pre-Specified Interim Results from PROTECTIVE-2 (Study 106) Phase 3, Demonstrating Plinabulin’s Superiority in Combination with Neulasta for CIN Prevention vs. Neulasta...
BeyondSpring to Host Second-Quarter 2020 Financial Results and Operational Update Conference Call on September 3rd, 2020
August 27, 2020 08:00 ET
|
BeyondSpring, Inc.
NEW YORK, Aug. 27, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer...
BeyondSpring Appoints Forty Seven, Inc., Co-Founder and Stanford Hematology Veteran, Dr. Ravindra Majeti, to Board of Directors
August 18, 2020 08:00 ET
|
BeyondSpring, Inc.
NEW YORK, Aug. 18, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative...
BeyondSpring Initiates Expanded Access Program with Plinabulin for Patients Suffering from CIN in the U.S.
August 11, 2020 08:00 ET
|
BeyondSpring, Inc.
- NCCN Guideline Updates Highlight Need for Maximum CIN Prevention and Resource Allocation for COVID-19 Patients - - First Patient Dosed in the U.S. Avoided Grade 4 Neutropenia in Cycle 2 with...
New Stem Cell-Based Application for BeyondSpring’s Plinabulin Presented at ISSCR Annual Meeting
June 30, 2020 07:00 ET
|
BeyondSpring, Inc.
NEW YORK, June 30, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative...
New Preclinical Data Demonstrates Immune-Enhancing Effects of Triple I/O Combination Therapy with BeyondSpring’s Plinabulin
June 23, 2020 08:00 ET
|
BeyondSpring, Inc.
Research Presented at 2020 AACR Virtual Annual MeetingThe Triple I/O Combination of Plinabulin, Anti-PD-1 and Radiation Achieved a 100 Percent Complete Response in Anti-PD-1 Non-responsive Animal...
BeyondSpring Announces Pricing of Ordinary Shares
June 19, 2020 05:31 ET
|
BeyondSpring, Inc.
NEW YORK, June 19, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative...
BeyondSpring Announces Proposed Public Offering of Ordinary Shares
June 18, 2020 16:06 ET
|
BeyondSpring, Inc.
NEW YORK, June 18, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative...
BeyondSpring Announces Positive Topline Interim Results from PROTECTIVE-2 (Study 106) Phase 3 Trial Evaluating Superiority of Plinabulin in Combination with Neulasta for Chemotherapy-Induced Neutropenia Prevention
June 15, 2020 07:00 ET
|
BeyondSpring, Inc.
-Met Primary Endpoint of Rate of Severe (Grade 4) Neutropenia Prevention in First Chemotherapy Cycle (Cycle 1) (p<0.01)- -Met Key Secondary Endpoint of Duration of Severe Neutropenia (DSN) of...
BeyondSpring Reports First-Quarter 2020 Financial Results and Operational Update
June 11, 2020 08:00 ET
|
BeyondSpring, Inc.
- PROTECTIVE-2 (Study 106) Phase 3 Interim Analysis This Month to Evaluate Superiority in CIN - - PROTECTIVE-2 Phase 2 Shows Positive Results in Chemotherapy Optimization with Potentially Better...